X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's YL211, a next-generation antibody-drug conjugate specifically targeting c-Mesenchymal-epithelial transition factor against solid tumors.
Lead Product(s): YL211
Therapeutic Area: Oncology Product Name: YL211
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,000.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration January 02, 2024
Details:
Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets, against Human Epidermal Growth Factor Receptor 3 (HER3).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $1,070.0 million Upfront Cash: $70.0 million
Deal Type: Licensing Agreement October 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
